MA27634A1 - Traitement de maladies proliferatives au moyen de derives d'epothilone et d'une exposition a des rayonnements - Google Patents

Traitement de maladies proliferatives au moyen de derives d'epothilone et d'une exposition a des rayonnements

Info

Publication number
MA27634A1
MA27634A1 MA28512A MA28512A MA27634A1 MA 27634 A1 MA27634 A1 MA 27634A1 MA 28512 A MA28512 A MA 28512A MA 28512 A MA28512 A MA 28512A MA 27634 A1 MA27634 A1 MA 27634A1
Authority
MA
Morocco
Prior art keywords
treatment
radiation exposure
proliferative diseases
epothilone derivatives
epothilone
Prior art date
Application number
MA28512A
Other languages
English (en)
Inventor
Martin Pruschy
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA27634A1 publication Critical patent/MA27634A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

La présente invention concerne des composés organiques de formule (I), notamment des compositions pharmaceutiques à utiliser en combinaison avec une exposition à des rayonnements ionisants afin de retarder la progression ou de traiter une maladie proliférative, en particulier une maladie à tumeur solide.
MA28512A 2003-03-14 2005-09-23 Traitement de maladies proliferatives au moyen de derives d'epothilone et d'une exposition a des rayonnements MA27634A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0305928.4A GB0305928D0 (en) 2003-03-14 2003-03-14 Organic compounds

Publications (1)

Publication Number Publication Date
MA27634A1 true MA27634A1 (fr) 2005-11-01

Family

ID=9954825

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28512A MA27634A1 (fr) 2003-03-14 2005-09-23 Traitement de maladies proliferatives au moyen de derives d'epothilone et d'une exposition a des rayonnements

Country Status (25)

Country Link
US (2) US20070129411A1 (fr)
EP (1) EP1605937B1 (fr)
JP (1) JP4927530B2 (fr)
KR (1) KR20050109988A (fr)
CN (2) CN1758908A (fr)
AT (1) ATE491450T1 (fr)
AU (1) AU2004218927A1 (fr)
BR (1) BRPI0408366A (fr)
CA (1) CA2519037A1 (fr)
DE (1) DE602004030545D1 (fr)
ES (1) ES2358109T3 (fr)
GB (1) GB0305928D0 (fr)
IL (1) IL170632A (fr)
IS (1) IS8059A (fr)
MA (1) MA27634A1 (fr)
MX (1) MXPA05009808A (fr)
NO (1) NO20054723L (fr)
NZ (1) NZ542305A (fr)
PL (1) PL1605937T3 (fr)
PT (1) PT1605937E (fr)
RU (1) RU2381799C2 (fr)
TN (1) TNSN05226A1 (fr)
TW (1) TWI358295B (fr)
WO (1) WO2004080458A1 (fr)
ZA (1) ZA200506942B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242469B1 (en) 1996-12-03 2001-06-05 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
WO2004018478A2 (fr) 2002-08-23 2004-03-04 Sloan-Kettering Institute For Cancer Research Synthese d'epothilones, leurs intermediaires, leurs analogues et leurs utilisations
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP1640004A1 (fr) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Utilisation des epothilones pour le traitement des metastases osseuses ou du cancer des os
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
CN103037903A (zh) 2010-05-18 2013-04-10 天蓝制药公司 用于治疗自身免疫性疾病或其它疾病的组合物和方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6033645A (en) * 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
US6242469B1 (en) * 1996-12-03 2001-06-05 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
JP2001288097A (ja) * 2000-04-07 2001-10-16 Pg-Txl Co Lp 水溶性パクリタキセル誘導体
PL207720B1 (pl) * 2001-01-25 2011-01-31 Bristol Myers Squibb Co Sposób przygotowania preparatu farmaceutycznego i jego zastosowanie, farmaceutyczny produkt oraz sposób wytwarzania kompozycji farmaceutycznej
CA2440555A1 (fr) * 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combinaison d'analogues d'epothilones et d'agents chimiotherapeutiques servant au traitement de maladies proliferatives

Also Published As

Publication number Publication date
RU2005131723A (ru) 2007-08-20
BRPI0408366A (pt) 2006-03-21
IL170632A (en) 2012-01-31
NO20054723L (no) 2005-10-13
WO2004080458A1 (fr) 2004-09-23
TWI358295B (en) 2012-02-21
CN1758908A (zh) 2006-04-12
NZ542305A (en) 2009-03-31
ZA200506942B (en) 2006-07-26
TW200505444A (en) 2005-02-16
GB0305928D0 (en) 2003-04-23
PT1605937E (pt) 2011-03-17
ATE491450T1 (de) 2011-01-15
RU2381799C2 (ru) 2010-02-20
DE602004030545D1 (de) 2011-01-27
IS8059A (is) 2005-10-04
CN101804050A (zh) 2010-08-18
HK1086493A1 (en) 2006-09-22
JP4927530B2 (ja) 2012-05-09
ES2358109T3 (es) 2011-05-05
US20070129411A1 (en) 2007-06-07
AU2004218927A1 (en) 2004-09-23
US20120053559A1 (en) 2012-03-01
EP1605937B1 (fr) 2010-12-15
EP1605937A1 (fr) 2005-12-21
KR20050109988A (ko) 2005-11-22
TNSN05226A1 (en) 2007-06-11
JP2006520353A (ja) 2006-09-07
PL1605937T3 (pl) 2011-05-31
CA2519037A1 (fr) 2004-03-23
MXPA05009808A (es) 2005-10-26

Similar Documents

Publication Publication Date Title
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
CY1111050T1 (el) Φωσφονικα, μονοφωσφοναμιδικα, διφωσφοναμιδικα για την αγωγη των ιϊκων παθησεων
ATE370139T1 (de) Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
DE602004014170D1 (de) Benzylether- und benzylamino-beta-sekretase-hemmer zur behandlung von alzheimer-krankheit
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
ATE507204T1 (de) Isoindolin-verbindungen und deren verwendungen
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
EP1572118A4 (fr) Methodes et compositions de traitement de cancer au moyen des genes 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
EA200701930A1 (ru) Производные пиримидина для лечения гиперпролиферативных нарушений
DK1809288T3 (da) Anvendelse af 1,4-bis-(3-aminoalkyl)piperazinderivater ved behandling af neurodegenerative sygdomme
BR0309996A (pt) Composto, composição farmacêutica, método de tratar ou melhorar doenças ou condições proliferativas, uso de um composto, e, método de tratar ou melhorar doenças inflamatórias
ATE491450T1 (de) Behandlung proliferativer erkrankungen mit epothilon-derivaten und bestrahlung
ATE412411T1 (de) Pmcol zur behandlung von prostatakrebs
ATE327240T1 (de) 2ß OXO-VORUSCHARIN UND DERIVATEN
TW200510348A (en) 5-aryltetrazole compounds, compositions thereof, and uses therefor
HN2002000311A (es) Benzoimidazoles